XML 51 R35.htm IDEA: XBRL DOCUMENT v3.24.3

Accrued Expenses and Other Current Liabilities (Tables)

9 Months Ended

12 Months Ended

Sep. 30, 2024

Dec. 31, 2023

Accrued Liabilities and Other Liabilities [Abstract]

Schedule of Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consist of the following (in thousands):

		September 30, 2024				December 31, 2023
Marketing reimbursement		$	930			$	2,834
Accrued compensation			1,733				1,687
Accrued clinical trials and R&D			81				3,694
Accrued selling and marketing			592				1,110
Accrued professional fees			493				1,505
Accrued warranty			16				44
Accrued restructuring			—				655
Other accrued expenses			4,128				3,966
Total accrued expenses and other current liabilities		$	7,973			$	15,495

Accrued expenses and other current liabilities consist of the following (in thousands):

		December 31,
		2023				2022
Distributor fees and marketing reimbursements		$	2,834			$	6,348
Accrued compensation			1,687				3,453
Accrued clinical trials and R&D			3,694				228
Accrued selling and marketing			1,110				481
Accrued professional fees			1,505				2,105
Accrued interest			—				489
Accrued warranty			44				48
Accrued restructuring			655				—
Other accrued expenses			3,966				2,641
Total accrued expenses and other current liabilities		$	15,495			$	15,793

X

- References

No definition available.

+ Details

Name:	us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the components of accrued liabilities.

+ References

No definition available.

+ Details

Name:	us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration